Cumberland Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: CPIX · Form: 8-K · Filed: Apr 29, 2024 · CIK: 1087294
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K for shareholder vote matters - details TBD.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on April 29, 2024, to report on a submission of matters to a vote of security holders. The filing does not contain specific details about the matters to be voted on or any financial figures.
Why It Matters
This filing indicates that Cumberland Pharmaceuticals Inc. is convening a meeting or seeking shareholder approval for certain corporate actions, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any new financial information or significant corporate events that would immediately impact risk.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
- April 29, 2024 (date) — Date of Report
- 2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 (address) — Principal Executive Offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters within the provided text.
When is the date of the shareholder vote or meeting?
The filing indicates the report date is April 29, 2024, and the earliest event reported is also April 29, 2024, but does not specify the date of the vote itself.
Are there any financial implications disclosed in this filing?
No specific financial figures or implications are disclosed in the provided text of this 8-K filing.
What is Cumberland Pharmaceuticals Inc.'s primary business?
Cumberland Pharmaceuticals Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.
Where is Cumberland Pharmaceuticals Inc. headquartered?
The company's principal executive offices are located at 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-29 16:53:33
Filing Documents
- cpix-20240429.htm (8-K) — 31KB
- 0001628280-24-019053.txt ( ) — 152KB
- cpix-20240429.xsd (EX-101.SCH) — 2KB
- cpix-20240429_lab.xml (EX-101.LAB) — 21KB
- cpix-20240429_pre.xml (EX-101.PRE) — 12KB
- cpix-20240429_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On April 23, 2024, the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the "Company") was held in Nashville, Tennessee. The following matters were voted upon and approved by the Company's shareholders: (1) the election of two (2) Class II Directors; (2) the ratification of the appointment of Carr, Riggs & Ingram, LLC as our independent registered public accounting firm for the year ending December 31, 2024; The voting results were as follows: For Against Withheld Abstentions % of Votes in Favor Martin S. Brown, Jr. 8,544,756 — 352,239 — 96.0% James R. Jones 8,411,468 — 485,527 — 94.5% Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2024 11,189,440 15,502 — 28,560 99.9%
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: April 29, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer